Content Type: Article

  • Paycheck Protection Program Update: Guidance on Affiliation, Clarification on Eligibility and New Forms

    Paycheck Protection Program Update: Guidance on Affiliation, Clarification on Eligibility and New Forms

    ARTICLE / CLIENT ALERT

    Paycheck Protection Program Update: Guidance on Affiliation, Clarification on Eligibility and New Forms

    April 6, 2020

    Read time: 15 min

    Key takeaways
    Overview

    The Small Business Administration (“SBA”) and the U.S. Department of the Treasury (“Treasury”) have provided additional information and forms to borrowers and lenders on the SBA’s affiliation rules and necessary forms with respect to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”).

    On April 3, 2020, the SBA promulgated a second Interim Final Rule[1] (“Supplemental Rule”) supplementing the Interim Final Rule issued by the SBA on April 2, 2020 (“Implementing Rule”), which implemented the PPP. The Supplemental Rule provides additional guidance on the application of certain affiliate rules applicable to the PPP. Further, on April 3, 2020, the Treasury issued guidance on the four affiliation tests that the SBA uses in determining whether an applicant, other than those specifically waived or exempted, should aggregate its employees or revenue (as applicable) with those of another business for purposes of determining an applicant’s eligibility under the PPP.

    This Alert (i) provides an overview of the four affiliation tests and discusses the implications of such for fund managers and their portfolio companies;[2] (ii) addresses an inconsistency between the Supplemental Rule and Implementing Rule with regard to the eligibility criteria; and (iii) describes the application forms currently available on the Treasury’s website.

    I. New Guidance on Affiliation/Aggregation

    The Treasury’s recently issued guidance, together with the Supplemental Rule, further clarified the SBA’s affiliation rules with respect to businesses seeking to apply for a PPP loan.

    Affiliation Defined

    Under the SBA’s affiliation rules, an applicant is deemed to be affiliated with another business when (i) one controls or has the power to control the other; or (ii) a third party or multiple third parties controls or has the power to control both. Affiliation is found when the power to control exists, and it does not matter whether such control is actually exercised.

    Four Affiliation Tests

    Unless subject to a waiver or exemption (as described below), affiliation under any of the following four tests is sufficient to establish affiliation for applicants applying for a PPP loan.[3] Thus, applicants should consider whether its relationship (or relationship of any person that controls such applicant) with another individual or entity would be considered an affiliation under the SBA’s affiliation rules and, thus, impacts the eligibility for a PPP loan.

    1. Affiliation Based on Ownership

    If an individual or entity owns or otherwise has the power to control more than 50% of an entity’s voting equity, affiliation between such persons will exist. Alternatively, if no individual or entity owns or otherwise has the power to control more than 50% of the voting equity of the entity, the SBA will deem such entity’s board of directors, officers, managing members or partners that control the management of the entity to be in control for this purpose.

     

    Minority shareholders may also trigger the SBA’s affiliation rules under this test in such cases where a minority shareholder (whether an individual or an entity) has the ability, under the entity’s charter or bylaws, or a shareholder’s agreement, to prevent a quorum or otherwise block action by the board of directors or shareholders.

    2. Affiliation Arising Under Stock Options, Convertible Securities and Agreements to Merge

    The SBA considers stock options, convertible securities and any merger or sale agreements (including agreements in principle) to have a present effect on the power to control a business, and thus, the SBA treats the foregoing as though the rights granted thereunder have already been exercised. The same should not be treated as having present effect when they are subject to conditions precedent that are incapable of fulfillment, speculative, conjectural or unenforceable under applicable law or where the exercise of such or the probability of a transaction is “extremely remote.” Further, any agreements to open or continue negotiations towards the possibility of a merger or sale are not given present effect.

    Notably, an individual or entity that controls one or more entities cannot use options, convertible securities or other agreements to terminate such control before actually doing so. The SBA will not give present effect to such individual’s or entity’s ability to divest all or part of their ownership interest in order to avoid the finding of affiliation.

    3. Affiliation Based on Management

    Affiliation may arise where an applicant’s management[4] shares common management with another entity or where an individual or other entity controls the board of directors or management of multiple entities. Affiliation can also be found where an individual or entity controls the management of the applicant through a management agreement.

    4. Affiliation Based on Identity of Interest

    Affiliation rules may arise where there is an identity of interest between close relatives[5] with identical, or substantially identical, business or economic interests. For example, the SBA can find affiliation where such close relatives operate businesses in the same or similar industry in the same geographic area. However, in such case, the applicant can rebut the SBA’s determination by offering evidence to show that the interests or businesses are, in fact, separate.

    Waived and Exempt Organizations

    As discussed in our initial March 30, 2020 Alert, the affiliation rules do not apply to the following small businesses applying for a PPP loan (i) businesses in the “accommodation and food services” sector;[6] (ii) businesses operating as a franchise; or (iii) businesses receiving financial assistance from a small business investment company.[7]

    The Supplemental Rule also exempts faith-based organizations from the affiliation rules where its relationship to another faith-based organization is based on a religious teaching or belief or otherwise constitutes part of the exercise of religion.

    Implications for Fund Managers and Portfolio Companies

    Fund managers should carefully review their ownership interests in, and other agreements or relationships with, their portfolio companies to determine whether any of their portfolio companies would be considered affiliates of the manager, and each other, for purposes of determining eligibility for a PPP loan. Further, fund managers will also want to review their owners’ outside business interests (e.g., ownership interests, board positions, etc.) to determine whether any other business should be affiliated with the fund manager (and any affiliated portfolio companies) under the PPP, even if such business is unrelated to the fund manager.

    II. Clarification On Eligibility Criteria

    The Supplemental Rule calls into question the Implementing Rule’s statement of the PPP eligibility test applicable to for-profit businesses. In the Implementing Rule, the SBA wrote, with regard to for-profit businesses:

    You are eligible for a PPP loan if you have 500 or fewer employees whose principal place of residence is in the United States, or are a business that operates in a certain industry and meet the applicable SBA employee-based size standards for that industry, and

    1. You are:
    1. A small business concern as defined in section 3 of the Small Business Act (15 USC 632), and subject to SBA’s affiliation rules under 13 CFR 121.301(f) unless specifically waived in the [CARES] Act … (emphasis added).

    However, in the Supplemental Rule, the SBA notes, with regard to for-profit businesses:

    An entity generally is eligible for the PPP if it, combined with its affiliates, is a small business as defined in section 3 of the Small Business Act (15 U.S.C. 632), or (1) has 500 or fewer employees whose principal place of residence is in the United States or is a business that operates in a certain industry and meets applicable SBA employee-based size standards for that industry … (emphasis added).

    Accordingly, while the Implementing Rule explicitly indicates that an applicant must (1) have no more than 500 employees or the applicable SBA employee-based size standards for its industry; and (2) qualify as a small business concern under the Small Business Act, the Supplemental Rule seems to indicate that an applicant must only satisfy either of those requirements, but not both. This issue is important because it determines whether certain applicants could be excluded from the PPP based on a revenue test, even if they do not exceed the applicable employee size limit.

    Because the Supplemental Rule is the SBA’s most recent pronouncement on the PPP, it could be assumed that it supersedes the Implementing Rule and reflects the SBA’s current intent. On the other hand, the purpose of the Supplemental Rule is to provide guidance on the application of the SBA’s general affiliation rules to the PPP (as more fully described below) and only mentions the eligibility rules as a preface to doing so. In contrast, the Implementing Rule is the operative authority for implementation of the PPP, including eligibility.

    However, a plain language reading of the CARES Act appears to support the interpretation in the Supplemental Rule. The relevant CARES Act provision states:

    During the covered period, in addition to small business concerns, any business concern, nonprofit organization, veterans organization, or Tribal business concern described in section 31(b)(2)(C) shall be eligible to receive a covered loan if the business concern, nonprofit organization, veterans organization, or Tribal business concern employs not more than the greater of —

    (I) 500 employees; or

    (II) if applicable, the size standard in number of employees established by the Administration for the industry in which the business concern, nonprofit organization, veterans organization, or Tribal business concern operates (emphasis added).

    Therefore, consistent with the language in the Supplemental Rule, the CARES Act appears to permit another segment of businesses to qualify for PPP loans, in addition to those businesses that may qualify for such loans as small business concerns under the Small Business Act. Accordingly, while the issue is not entirely free from doubt until the SBA issues further guidance, at this time we believe that an otherwise eligible applicant whose workforce does not exceed the applicable size limit should not refrain from applying solely because it does not qualify as a small business concern under the Small Business Act. However, it appears that applicants conducting a business normally ineligible for SBA business loans are still ineligible under the PPP (except for nonprofit organizations authorized under the CARES Act),[8] even if they have an eligibly-sized workforce.

    III. New Forms Available for Borrowers and Lenders

    As we noted in our April 3, 2020 Alert, the SBA requires certain forms to be completed in connection with participating as either a borrower or lender in the PPP. Versions of three of those forms have now been made available on the Treasury’s website.

    Most notably still absent is the forthcoming application for nonbanks to become approved PPP lenders. As noted in our April 3, 2020 Alert, the SBA’s Implementing Rule indicated that any non-depository financing provider would be eligible to become a PPP lender so long as such provider (i) originates, maintains and services business loans or other commercial financial receivables and participation interests; (ii) has a formalized compliance program; (iii) applies the requirements under the Bank Secrecy Act (“BSA”) as a federally regulated financial institution, or the BSA requirements of an equivalent federally regulated financial institution; (iv) has been operating since at least Feb. 15, 2019; and (v) has originated, maintained and serviced more than $50 million in business loans or other commercial financial receivables during a consecutive 12-month period in the past 36 months, or is a service provider to any insured depository institution that has a contract to support such institution’s lending activities and is in good standing with the appropriate federal banking agency. However, so far, no instructions have been given on how such institutions can apply.

    1. CARES Act Section 1102 Lender Agreement

    As noted in our April 3, 2020 Alert, all previously approved lenders under the SBA’s 7(a) program were automatically approved to make PPP loans. Previously unapproved entities within the following categories will automatically qualify upon submission of this agreement (SBA Form 3506) (i) federally insured depository institutions; (ii) federally insured credit unions; and (iii) Farm Credit System institutions (other than the Federal Agricultural Mortgage Corporation) that apply the requirements under the BSA and its implementing regulations as federally regulated financial institutions, or functionally equivalent requirements. As noted above, such entity cannot be (i) designated in Troubled Condition by its primary federal regulator; or (ii) subject to formal enforcement action by its primary federal regulator that addresses unsafe or unsound lending practices. Lenders will have to provide certain administrative information as well, such as indicating its primary federal regulator and any applicable lender identifiers.

    The terms of the agreement govern only such applicable PPP lenders and will remain in effect even after the SBA repurchases such loans, but terminate such lender’s authority to make a PPP loan on July 1, 2020. Under the agreement, lenders must process and approve PPP loans under the delegated authority of the SBA — without the SBA’s prior review and approval — and must assume all obligations, responsibilities and requirements associated therewith. Notably, the agreement states that lenders will be responsible for all decisions concerning the eligibility of a borrower for a PPP loan. Such lenders must also ensure that all documentation held by such lenders which relate to the PPP loans are properly executed and otherwise fulfill the requirements of the PPP. However, as noted in our April 3, 2020 Alert, the Implementing Rule explicitly states that the SBA will allow PPP lenders to rely on borrower certifications and specified documents to determine PPP loan eligibility and to determine the amount of loan proceeds for which the borrower qualifies. Notably, the Interim Final Rule relieves lenders of any liability for providing a PPP loan to any borrower that factually does not meet the SBA’s criteria, but fraudulently certifies that it does.

    Under the agreement, lenders are to receive all principal and interest payments unless the SBA directs otherwise. Lenders must also service and liquidate all PPP loans and will bear all associated responsibility in doing so. Lenders may demand that the SBA repurchase PPP loans, and, in doing so, represent that all of such loans are in compliance with the PPP. The only fee permitted to be charged in connection with a PPP loan is the 1% interest rate. No other bonus, fee, prepayment penalty, commission or other payment or benefit from a borrower is permitted.

    Both lenders and the SBA may terminate this agreement with 10 days’ written notice by certified mail to the other party. In the event of termination, the SBA’s guaranty will remain in effect and lenders must comply with PPP requirements for any loans made before termination. Importantly, lenders must comply with an SBA demand to purchase a guaranty or request to extend the maturity or the lender will automatically lose the SBA’s guaranty. This agreement may also be assigned by any lender with the SBA’s prior written consent, which the SBA may withhold in its sole discretion.

    2. Borrower Application Form

    The SBA also published a modified application form (SBA Form 2483) for potential borrowers seeking a PPP loan.[9] The application largely remains the same as the form published on March 31, 2020 (see our prior Alert). This version does clarify that the borrower must provide the number of employees being counted for purposes of the PPP loan. In addition, the modified application adds certain questions aimed at determining a potential borrower’s eligibility, which ask whether (i) all employees used to calculate the applicant’s payroll calculation have a principal place of residence in the United States; and (ii) the applicant is a franchise listed in the SBA’s Franchise Directory. The modified application also adds certain certifications, including (i) that the applicant will use PPP loans for business-related purposes as it specifies in the application; and (ii) that any Economic Injury Disaster Loan (“EIDL”) it receives will be used for purposes other than those allowable under the PPP.

    3. Lender Application Form — Paycheck Protection Program Loan Guaranty

    The PPP Loan Guaranty form (SBA Form 2484) is required to be submitted by any SBA-approved lender participating in the PPP and is the means by which the SBA will repurchase PPP loans or loan pools. The form requires a lender to (i) submit administrative information on both the lender and the borrower (e.g., name, address, contact information, etc.); (ii) describe the structure of the PPP loan issued, including setting forth the amount of the loan, the borrower’s average monthly payroll multiplied by 2.5 and the amount of any refinanced EIDL; (iii) attest to the borrower providing certain certifications to it; and (iv) make certain self-certifications, including (a) that it has complied with its obligations under the PPP; (b) that it has obtained and reviewed all required documents from the borrower and will retain such documents; and (c) that neither the authorized lender official signing the form, nor his or her spouse or children, have a financial interest in the borrower. The lender must also indicate whether it used an agent or other third party to assist in preparing the loan or loan application materials or to otherwise assist in services with respect to the loan.

    Authored by Joseph P. Vitale, Andrew J. Fadale, Stuart D. Freedman, Jessica Romano, David M. Rothenberg and Adam J. Barazani.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] https://home.treasury.gov/system/files/136/SBA%20IFR%202.pdf.

    [2] For additional information on loans available under the PPP, please see our April 3, 2020 Alert.

    [3] See also 13 C.F.R. § 121.301(f).

    [4] This can include the chief executive officer, President or other officers, managing members or partners that have the power to control the business.

    [5] A “close relative” is a spouse, parent, child or sibling, or the spouse of any such person. 13 C.F.R. § 120.10.

    [6] As determined under NAICS.

    [7] A small business investment company is any licensed under section 301 of the Small Business Investment Act of 1958 for purposes of providing “private equity capital and long-term loan funds” to small businesses for small-business-related concerns.

    [8] A list of such ineligible businesses appears at 13 CFR § 120.110 and is further discussed in SBA Standard Operating Procedure 50 10, Subpart B, Chapter 2. For more information, please see our April 3, 2020 Alert.

    [9] This form has been included in previous SRZ Alerts, but note that the form has been updated multiple times in the past several days.


    This is a fast-moving topic and the information contained in this Alert is current as of the date it was published.

    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Adam J. Barazani

    Partner

    New York – 919 Third Avenue

    More insights

  • Exemptions and Considerations for the Treatment of Opioid Use Disorder During the COVID-19 Emergency

    Exemptions and Considerations for the Treatment of Opioid Use Disorder During the COVID-19 Emergency

    ARTICLE / CLIENT ALERT

    Exemptions and Considerations for the Treatment of Opioid Use Disorder During the COVID-19 Emergency

    April 5, 2020

    Read time: 5 min

    Key takeaways
    Overview

    The Substance Abuse and Mental Health Services Administration (SAMHSA) has published new guidance for the care and treatment of substance use disorders during the COVID-19 outbreak. Of note, the guidance includes specific exemptions relating to the provision of methadone and buprenorphine to treat opioid use disorder and addresses other factors that should be considered when providing treatment for alcohol or benzodiazepine withdrawal.

    In depth

    On March 19 and 20, 2020, the Substance Abuse and Mental Health Services Administration (SAMHSA) published new guidance for the care and treatment of mental and substance use disorders during the Coronavirus (COVID-19) outbreak. This guidance includes exemptions for providers working in opioid treatment programs (OTPs) relating to (i) the provision of methadone and buprenorphine to treat opioid use disorder and (ii) other factors that should be considered while managing treatment of alcohol or benzodiazepine withdrawal.

    Specifically, OTPs are no longer required to perform an in-person evaluation (pursuant to 42 C.F.R. § 8.12(f)(2)) of any patients treated with buprenorphine if a program physician, primary care physician, or authorized healthcare professional under the supervision of a program physician determines that an adequate evaluation of the patient can be accomplished via telehealth. This exemption is exclusive to patients requiring treatment with buprenorphine and does not apply to new patients treated with methadone. For patients treated with methadone, an in-person evaluation is still required.

    Treatment of OTP buprenorphine patients must occur in accordance with SAMHSA’s OTP guidance issued on March 16, 2020, which allows states to request blanket exceptions for all stable patients in an OTP to receive up to 28 days of take-home doses of the patient’s medication for opioid use disorder or up to 14 days of take-home medication for those patients who are less stable but who the OTP believes can safely handle this level of take-home medication.

    OTPs may continue to treat existing patients with both buprenorphine and methadone via telehealth (including telephonically). Further, OTPs may dispense medication (both buprenorphine and methadone) under a blanket exemption based on telehealth evaluation (including telephone) using the following guidelines: (i) up to 28 doses for clinically stable patients or (ii) up to 14 doses for less clinically stable patients. Additionally, as outlined in a previous On the Subject, the DEA has eased restrictions on prescribing controlled substances via telehealth and has also loosened the delivery and administration requirements for methadone during the period of the national emergency.

    In the event that a supervising physician can no longer oversee the administration or dispensing of medication-assisted treatment (MAT) medications, OTP mid-level providers may continue to dispense and administer such medications within an OTP, without the direct supervision of an OTP physician, if such mid-level practitioner is “licensed under the appropriate State law and registered under the appropriate State and Federal laws to administer or dispense opioid drugs” pursuant to 42 C.F.R. § 8.12(h)(1).

    Lastly, in the event that an OTP physician or medical director cannot perform his or her regulatory functions pursuant to 42 C.F.R. § 8.12, an OTP may request an exemption from the requirements of 42 C.F.R. § 8.12 in order to permit midlevel providers to perform those functions related to admitting patients, ordering unsupervised take home medication, or changing medication doses if such action is consistent with applicable state law and the midlevel provider’s scope of licensure.

    These exemptions will continue for the period of the national emergency declared in response to the COVID-19 pandemic. It is also important to note that state laws may impact the practicality of these exemptions, particularly as states continue to make emergency proclamations and promulgate executive orders on a daily basis.

    Other Considerations for Providers

    SAMHSA has also provided several factors for providers to consider while managing treatment of alcohol or benzodiazepine withdrawal, particularly as access to care facilities becomes limited. Specifically, SAMHSA has recommended the use of intensive outpatient treatment services whenever possible, and that inpatient facilities should be preserved for patients for whom outpatient measures would not be adequate (e.g., patients diagnosed with life-threatening mental disorders, such as a severe depression, and exhibiting suicidal tendencies). SAMHSA has also encouraged the use of telehealth and/or telephonic services to evaluate and treat patients, including for consideration of the use of buprenorphine products to treat opioid use disorder. Lastly, SAMHSA advises providers to consider CDC guidance when admitting new patients, while managing current residents who may have been exposed to or who are infected with COVID-19, and when reviewing or revising visitor polices.

    Authors

    George Tzanetakos

    Partner

    Chicago

    More insights

  • CMS Provides Guidance to Ambulatory Surgical Centers Temporarily Enrolling in Medicare as Hospitals During the COVID-19 Pandemic

    ARTICLE / CLIENT ALERT

    CMS Provides Guidance to Ambulatory Surgical Centers Temporarily Enrolling in Medicare as Hospitals During the COVID-19 Pandemic

    April 5, 2020

    Read time: 10 min

    Key takeaways
    Overview

    On April 3, 2020, the Centers for Medicare & Medicaid Services (CMS) issued Quality, Safety & Oversight memorandum QSO-20-24-ASC (the QSO Memo), addressed to state survey agencies to provide guidance on processing attestation statements from ambulatory surgical centers (ASCs) that are temporarily enrolling as hospitals during the Coronavirus (COVID-19) pandemic in accordance with Section 1135 waivers. Each ASC should carefully consider how the facility can meet applicable Medicare participation requirements for hospitals and ensure that conversion to a hospital is consistent with state licensure and state emergency preparedness and pandemic plans before converting its Medicare enrollment from an ASC to a hospital. ASCs and hospitals should also be mindful that the guidance released from CMS applies only to Medicare participation requirements and that ASC-to-hospital conversions must also be reviewed for compliance with federal and state fraud and abuse laws and other payor participation requirements.

    In depth

    On April 3, 2020, CMS issued the QSO Memo to provide direction to state survey agencies regarding the process for ambulatory surgery centers (ASCs) to temporarily enroll in Medicare as hospitals. Allowing ASCs to temporarily convert to hospitals is intended to support efforts to expand capacity and Medicare payment for inpatient and outpatient hospital services in light of the COVID-19 pandemic.

    Background

    On March 13, 2020, President Donald Trump declared anational emergency under the National Emergencies Act and made an under the Stafford Act. This announcement followed the January 31, 2020, declaration of a public health emergency under the Public Health Service Act by the Secretary of the US Department of Health and Human Services (HHS). These actions opened the door for the authorization of waivers of certain Medicare, Medicaid and Children’s Health Insurance Program (CHIP) requirements as provided by Section 1135 of the Social Security Act (collectively, Section 1135 waivers).

    In the most recent Section 1135 waivers published on March 30, 2020, CMS briefly noted that an ASC could enroll as a hospital during the public health emergency, provided the ASC satisfied Medicare hospital conditions of participation (CoPs) not waived by the Section 1135 waivers.

    CMS also provided a series of nationwide Section 1135 waivers applicable to the physician self-referral law (the Stark Law) on March 30, 2020. Specifically, one waiver addresses the ability of physician-owned ASCs to convert to a hospital to expand their capabilities to provide care to patients in light of the COVID-19 pandemic. Under the waiver, referrals by a physician owner to an ASC that converts to a temporary hospital may be permitted, provided the remuneration is “solely related to COVID-19 Purposes.” For additional details on the Section 1135 waivers applicable to the Stark Law, please see our analysis, here.

    Though the Section 1135 waivers issued on March 30 indicated that ASCs could temporarily convert to hospitals during the COVID-19 public health emergency, the QSO Memo contains the first detailed operational guidance regarding the process for an ASC to temporarily enroll in Medicare as a hospital during the pandemic.

    Process and Limitations for ASCs Enrolling as Hospitals

    Medicare-enrolled ASCs are temporarily permitted to enroll in Medicare as hospitals for the duration of the public health emergency, subject to certain limitations. An ASC must ensure that enrolling as a hospital is not inconsistent with the state’s emergency preparedness or pandemic plan.

    Enrolling an ASC as a Hospital

    Any Medicare-certified ASC that wishes to enroll as a hospital will need to complete the following steps:

    • Notify the Medicare administrative contractor (MAC) that serves their jurisdiction by calling the MAC’s provider enrollment hotline
    • Submit a signed attestation statement to the MAC.

    Once the ASC has submitted a signed attestation statement to the MAC, the MAC will review and send the attestation to the applicable CMS regional office (the RO). The RO will review the ASC’s attestation and will evaluate the ASC’s history of “immediate jeopardy” survey deficiencies, as discussed below. If the CMS RO’s historical survey review is favorable, the CMS RO will approve the attestation statement within two business days from receipt, assign a hospital CMS certification number (CCN) and send a final determination permitting the ASC’s enrollment (known as a tie-in notice) as a hospital to the MAC. The former ASC’s date of enrollment will be retroactive to the date when the attestation was accepted by the MAC.

    An on-site survey is not required for approval, but the CMS RO may authorize a survey by the state survey agency at a later date to ensure quality and safety requirements are met.

    An ASC can elect to revert back to ASC status at any time upon providing notice to the MAC. In addition, ASCs are expected to come back into compliance with ASC conditions for coverage and other federal participation requirements once there is no longer a need for the ASC to be a hospital under its state’s emergency preparedness or pandemic plan.

    Immediate Jeopardy Findings

    In reviewing the ASC’s attestation, the RO will review all past survey activity of the ASC to determine whether the facility has had any immediate jeopardy deficiencies in the previous three years. In general, an immediate jeopardy finding involves a determination by a state survey agency that the ASC has failed to comply with one or more conditions for coverage applicable to ASCs and that such noncompliance has caused, or is likely to cause, serious injury, harm, impairment or death to a patient. Immediate jeopardy is the most serious level of noncompliance, and requires immediate corrective action to prevent serious injury, harm, impairment or death from occurring or recurring.

    An ASC will be permitted to enroll as a hospital if the ASC has no immediate jeopardy-level findings in the previous three years, or if the immediate jeopardy findings were identified but subsequently removed through the normal state survey process.

    If the ASC has had any immediate jeopardy-level deficiencies cited by a state survey agency within the last year and enforcement activities are currently ongoing (i.e., the survey cycle remains open), the RO will not accept the ASC’s attestation and will notify the MAC that the ASC will be denied temporary hospital enrollment.

    Billing Implications

    ASCs will not be permitted to be enrolled in Medicare as an ASC and as a hospital at the same time. The ASC will have its ASC billing privileges deactivated for the duration of the time it is enrolled as a hospital and will be reimbursed as a hospital. At the end of the public health emergency, the RO will terminate the hospital CCN and send a tie-out notice to the applicable MAC. The MAC will deactivate the hospital billing privileges and reinstate the ASC billing privileges effective on the date the ASC terminates its hospital status. If the ASC wishes to participate as a hospital after the public health emergency has ended, it must submit form CMS-855A and undergo an initial survey by the state agency or accreditation organization in order to determine compliance with hospital CoPs.

    Compliance with Hospital Conditions of Participation

    Importantly, if an ASC chooses to temporarily enroll in Medicare as a hospital, the ASC must meet the hospital CoPs, to the extent such CoPs are not waived by Section 1135 waivers. The attestation statement highlights particular CoPs that must be satisfied, including the following:

    •  Nursing Services:
      • Ensure adequate numbers of licensed registered nurses and other personnel are available to provide nursing care to all patients as needed
      • Provide 24-hour nursing services furnished or supervised by a registered nurse
      • Ensure drugs and pharmaceuticals are prepared and administered in accordance with federal and state laws and according to the orders of the practitioner(s) responsible for the patient’s care.
    • Pharmaceutical Services:
      • Provide pharmaceutical services that meet the needs of the patients
      • Have a pharmacy directed by a registered pharmacist or a drug storage area under competent supervision
      • Provide a full-time, part-time or consultant pharmacist who is responsible for all activities of the pharmacy services
      • Provide an adequate number of personnel to ensure high-quality pharmaceutical services, including emergency services
      • Ensure drugs listed in Schedules II, III, IV and V of the Comprehensive Drug Abuse and Prevention and Control Act of 1970 are kept locked within a secure area.
    • Infection Control:
      • Appoint a qualified individual as the infection preventionist/infection control professional
      • Employ methods for preventing and controlling the transmission of infections within the hospital and between other providers
      • Create an infection control surveillance plan to control healthcare-acquired infections
      • Establish a hospital-wide antibiotic stewardship program in accordance with national standards.
    • Respiratory Services:
      •  Ensure that the facility has a director of respiratory care services who is a doctor of medicine or osteopathy and who is available on a full- or part-time basis to supervise and administer respiratory services
      • Ensure an adequate number of qualified respiratory therapists and technicians
      • Ensure all respiratory services are delivered in accordance with medical staff directives.

    Any other CoPs that are not waived by Section 1135 waivers must also be met before the facility converts to a hospital.

    Key Takeaways

    While ASCs may be eager to take advantage of the flexibility provided by CMS to enroll in Medicare as a hospital—which status includes higher reimbursement—compliance with hospital CoPs is a fundamental requirement of participating in Medicare as a hospital. The attestation that must be submitted by the ASC to convert into a hospital requires the facility to attest that it will meet all applicable federal participation requirements. Submission of this attestation before the facility confirms that it can and will meet all hospital CoPs could later expose the ASC to liability.

    Before moving forward with an ASC-to-hospital conversion, ASCs will also need to carefully consider state law implications. As an initial matter, the ASC must ensure that enrolling as a hospital is not inconsistent with the state’s emergency preparedness or pandemic plan. The ASC must also ensure that the state will allow for the ASC to be licensed as a hospital or otherwise provide and hold itself out as providing hospital-level services without a hospital license.

    While Medicare will recognize and reimburse a converted ASC for hospital services if the above requirements are satisfied, it is unclear whether other payors, including state Medicaid programs and commercial payors will similarly recognize and reimburse the ASC for services provided at hospital reimbursement rates after the facility converts from an ASC to a hospital.

    ASCs with physician owners must also consider federal and state fraud and abuse laws when deciding to temporarily convert to a hospital. While CMS has provided a nationwide blanket Stark Law waiver that permits referrals by a physician-owner to an ASC that temporarily converts to a hospital, use of the Stark Law waiver requires that the arrangement satisfies a COVID-19 purpose and the particular facts and circumstances of the arrangement should be considered and documented before the facility moves forward with a conversion. The Office of Inspector General (OIG) has not issued similar Anti-Kickback Statute waivers and documentation of the purpose of the arrangement is also important for assessing Anti-Kickback Statute compliance.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Sandra M. DiVarco

    Partner

    Chicago

    Monica Wallace

    Partner

    Chicago

    Caroline Reignley

    Partner

    Washington, DC

    More insights

  • COVID-19 – How the Government Can Help Save Companies in Germany

    ARTICLE

    COVID-19 – How the Government Can Help Save Companies in Germany

    April 5, 2020

    Read time: 2 min

    Key takeaways
    Overview

    In this article featured in Frankfurter Allgemeine Sonntagszeitung, Prof. Dr. Wilhelm Haarman discusses ways in which the government can help save German businesses in the face of the COVID-19 crisis without straining its resources.

    In depth
    Authors
    More insights

  • The Role of Telehealth in COVID-19 Response Efforts

    ARTICLE / CLIENT ALERT

    The Role of Telehealth in COVID-19 Response Efforts

    March 3, 2020

    Read time: 4 min

    Key takeaways
    Overview

    As encouraged by the Centers for Disease Control and Prevention, healthcare providers have a unique and pressing opportunity to use telehealth tools to address COVID-19 preparedness and offer telehealth services to potential COVID-19 patients. However, healthcare providers’ response to the COVID-19 outbreak highlights some of the barriers to the provision of telehealth services.

    In depth

    As the number of confirmed COVID-19 cases in the United States grows, healthcare providers are stepping up their response planning. To combat the spread of COVID-19, the Centers for Disease Control and Prevention (CDC) urged healthcare systems and providers to deploy all of the resources necessary to ensure health system preparedness. The CDC recommended the use of telehealth tools to help address COVID-19 preparedness and to assist in directing patients to the right level of healthcare for their medical needs.

    Healthcare providers have a unique and pressing opportunity to offer telehealth services to potential COVID-19 patients. At the same time, healthcare providers’ response to the COVID-19 outbreak highlights some of the barriers to the provision of telehealth services. Providers considering using telehealth as part of their COVID-19 response efforts should take the following factors into consideration:

    • While healthcare providers cannot diagnose COVID-19 through a telehealth visit, they can perform a number of services without requiring a patient to visit crowded medical facilities where the virus might be present. These services include performing initial patient screenings, assessing and assigning risk categories to patients, determining if a patient needs to seek diagnostic testing, and answering patient questions and offering treatment recommendations.
    • Deploying telehealth services is not without its challenges. The varying reimbursement policies of private, state and federal payers, as well as differing state-based medical licensing requirements, may burden providers and patients with confusion, economic inefficiencies and onerous processes in a difficult engagement context.
    • As part of the COVID-19 response discussions, telehealth advocates propose that the Centers for Medicare and Medicaid Services reduce or eliminate its long-standing telehealth reimbursement restrictions. This change would allow Medicare to pay for virtual visits during national emergencies, regardless of originating site or geographic location. There is also a push to waive the lengthy enrollment process telehealth providers must undergo to be paid by Medicare.
    • While telehealth has the potential to assist in a healthcare system’s response to COVID-19, providers still must comply with state laws and regulations that govern telehealth, including but not limited to professional licensure, scope of practice, standard of care and patient consent, in addition to the reimbursement requirements and limitations put into place by third-party payers.
      • Typically, telehealth providers must be licensed in the state in which the patient is located, although certain states have exceptions that telehealth providers may leverage in response to COVID-19.
      • Telehealth providers must practice within the scope of practice of the profession in which they are licensed and within the standard of care set forth by the governing professional board in a given state.
      • State telehealth laws may require a specific modality for telehealth consultations (e.g., audio-visual consultations). Likewise, third-party payers may require a specific modality for telehealth consultations for purposes of reimbursement.
    Authors

    Lisa Mazur

    Partner

    Chicago

    Marshall E. Jackson , Jr.

    Partner

    Washington, DC

    More insights

  • OCR Waives Penalties for Certain PHI Use, Disclosure by Business Associates During COVID-19 Emergency

    OCR Waives Penalties for Certain PHI Use, Disclosure by Business Associates During COVID-19 Emergency

    ARTICLE / CLIENT ALERT

    OCR Waives Penalties for Certain PHI Use, Disclosure by Business Associates During COVID-19 Emergency

    April 3, 2020

    Read time: 9 min

    Key takeaways
    Overview

    On April 2, 2020, the US Department of Health and Human Services, Office for Civil Rights announced that it will not impose civil money penalties against covered entity health care providers or their business associates for a business associate’s good faith use or disclosure of protected health information for public health and health oversight activities during the Coronavirus (COVID-19) nationwide public health emergency.

    In depth

    Last month, the US Department of Health and Human Services (HHS), Office for Civil Rights (OCR) waived its enforcement of particular HIPAA requirements to promote Covered Entity health care providers’ good faith use of telehealth during the COVID-19 pandemic. On April 2, 2020, OCR issued another Notification of Enforcement Discretion to announce that, effective immediately, it will not assess civil money penalties against covered entity health care providers or their business associates for violations of certain HIPAA provisions resulting from good faith uses and disclosures by business associates of protected health information (PHI) for public health and health oversight activities during the Coronavirus (COVID-19) nationwide public health emergency. We summarize below the key elements of the OCR notification and some practical considerations for HIPAA business associates.

    According to OCR, federal public health authorities and health oversight agencies, such as the Centers for Disease Control and Prevention (CDC) and Centers for Medicare and Medicaid Services (CMS); state and local health departments; and state emergency operations centers, have recently requested business associates to either share PHI with them or perform analytics on PHI to support COVID-19 mitigation and response efforts. The HIPAA Privacy Rule, however, often impedes the ability of business associates to timely use and share PHI for public health and health oversight activities related to COVID-19.

    The Privacy Rule only allows a business associate to use and disclose PHI for purposes expressly set forth in its business associate agreement (BAA) with a covered entity or as required by law. Absent a legal requirement, a business associate cannot disclose PHI to a public health authority, for instance, if the disclosure is not permitted or required under its BAA with the covered entity and made on the covered entity’s behalf. Likewise, a business associate cannot use PHI to perform data analytics for public health purposes unless permitted to do so by its BAAs with covered entities.

    OCR explains that some business associates have been unable to share and analyze PHI in the context of COVID-19 public health and oversight activities “because their BAAs do not expressly permit them to make such uses and disclosures of PHI.” Consequently, OCR is temporarily suspending its enforcement of several HIPAA Privacy Rule provisions against covered entity health care providers and their business associates in an effort to facilitate speedy information-sharing and cooperation with public health and health oversight agencies. In doing so, OCR seeks to remove regulatory barriers that can impede more robust and expedient sharing of PHI that could be used to track, control and manage the COVID-19 public health emergency.

    OCR’s notification will remain effective until the Secretary of HHS declares that the COVID-19 public health emergency no longer exists or upon the expiration of President Trump’s proclamation of a national emergency—whichever comes first.

    Applicability and Scope of OCR’s Enforcement Discretion

    OCR’s notification applies to HIPAA enforcement against covered entity health care providers and their business associates. The notification also presumably applies to enforcement against subcontractors (as defined by HIPAA) to which business associates outsource services involving the PHI of covered entity health care providers, as those subcontractors are also business associates under HIPAA.

    OCR’s notification does not provide enforcement relief to covered entity health plans or health care clearinghouses. The notification also seemingly does not extend to a business associate’s use and disclosure of PHI that it received or created when delivering services to covered entity health plans or health care clearinghouses.

    Pursuant to the notification, OCR will not impose penalties against covered entity health care providers and their business associates for violations of only the following four HIPAA Privacy Rule provisions in connection with the COVID-19 public health emergency (so long as certain conditions, discussed below, are satisfied):

    • Business Associates: Permitted Uses and Disclosures, 45 CFR § 164.502(a)(3)) (stating, in relevant part, that a business associate may use or disclose PHI only as permitted or required by its BAA or required by law, and cannot use or disclose PHI in a manner that would violate HIPAA if done by a covered entity)
    • Disclosures to Business Associates: Documentation, 45 CFR § 164.502(e)(2) (requiring covered entities and business associates to enter into written BAAs with their business associates and subcontractors, respectively, that meet the requirements for BAAs set forth in the HIPAA Privacy Rule)
    • Business Associate Contracts, 45 CFR § 164.504(e)(1) (requiring covered entities BAAs with their business associates to meet the content requirements set forth in the HIPAA Privacy Rule)
    • Business Associate Contracts with Subcontractors, 45 CFR § 164.504(e)(5) (requiring business associates’ BAAs with their subcontractors to meet the content requirements for BAAs set forth in the HIPAA Privacy Rule).

    OCR cautions that the notification does not extend enforcement relief to a covered entity’s or business associate’s obligations under other HIPAA Privacy Rule provisions, the HIPAA Security Rule or the HIPAA Breach Notification Rule.

    Conditions of OCR’s Enforcement Discretion

    In the notification, OCR sets forth two conditions that must be met before a covered entity health care provider or business associate can benefit from enforcement relief with respect to the four HIPAA Privacy Rule provisions listed above:

    • The business associate’s use or disclosure of the covered entity health care provider’s PHI must be made in good faith for public health activities or health oversight activities consistent with the HIPAA Privacy Rule at 45 CFR §§ 164.512(b) and 164.512(d); and
    • The business associate must inform the covered entity health care provider of such use or disclosure no later than 10 calendar days after the use or disclosure occurs or commences.

    OCR notes that good faith uses or disclosures of PHI for COVID-19 public health or oversight include, for example, uses and disclosures for or to (1) the CDC or a similar state-level public health authority for the purpose of preventing or controlling the spread of COVID-19, and (2) CMS or a similar state-level health oversight agency for the purpose of overseeing and assisting the health care system in relation to COVID-19 response efforts.

    Considerations for Business Associates

    OCR’s notification provides regulatory comfort to business associates of covered entity health care providers that have understandably been hesitant to use or share PHI for public health and oversight activities related to COVID-19. Before embarking on such uses or disclosures, however, business associates should consider the following:

    • Breach of Contract and Civil Liability Considerations. Although business associates that act in compliance with OCR’s notification are inoculated from regulatory enforcement, they could still face breach of contract or other civil claims if their actions under the notification violate the terms of their agreements with applicable covered entity health care providers. For instance, a business associate that uses the PHI of patients who tested positive for COVID-19 to create de-identified data for a public health authority may be in material breach of its contract with a health care provider if the contract prohibits or restricts de-identification activities. Business associates should consider the likelihood of such claims based on their customer contracts and relationships.
    • Customer Relations. Covered entity health care providers may bristle at a business associate’s disclosure of their PHI to public health authorities or health oversight agencies without first being consulted about the disclosure. Although the notification does not require business associates to notify covered entity health care providers until 10 days after a public health or health oversight disclosure, business associates should develop an appropriate customer communications strategy. For example, a business associate may preemptively notify all or a strategically important subset of covered entity health care provider customers that the business associate intends to participate in these activities, and open a line of communication with customers related to the same.
    • Minimum Necessary Standard. OCR’s notification does not relieve a business associate of its obligation to make reasonable efforts to use and disclose the minimum amount of PHI necessary to accomplish an intended purpose. Business associates should apply the Privacy Rule’s “minimum necessary” standard to limit the amount of PHI used and disclosed for the public health and oversight purposes described in the notification.
    • Other Applicable Federal or State Privacy Laws. A Business associate should evaluate whether the uses or disclosures discussed in the notification may run afoul of other applicable federal or state health information privacy laws, such as 42 CFR. Part 2 or state laws governing the confidentiality of sensitive categories of health information.
    • Security Safeguards. OCR has not waived its enforcement of the HIPAA Security Rule against business associates that use and disclose PHI for public health and oversight in connection with COVID-19. A business associate should ensure that it applies reasonable and appropriate technical, administrative and physical safeguards to protect any electronic PHI used or disclosed for such public health and oversight activities. OCR recommends, for instance, that a business associate ensure that it securely transfers any electronic PHI to a public health authority or health oversight agency.
    • Breach or Incident Notification. In the event that a business associate suffers a breach of unsecured PHI, unauthorized use or disclosure, or security incident involving PHI it is processing for COVID-19 public health or oversight activities, the business associate may have reporting obligations under the HIPAA Breach Notification Rule and applicable BAAs with covered entity health care providers.
    • Accounting of Disclosures. A business associate that discloses PHI to a public health authority or health oversight agency should document such disclosure to enable the covered entity health care providers to comply with patients’ requests for accountings of disclosures of their PHI. The business associate’s 10-day notice to the covered entity health care providers required by the notification may be insufficient to comply with any BAA provisions requiring the business associate to maintain documentation relevant to an accounting of disclosures, particularly if the business associate did not provide written notice to the health care provider concerning the disclosure.
    Authors
    More insights

  • COVID-19 – An Overview of Competition Law in Germany

    ARTICLE

    COVID-19 – An Overview of Competition Law in Germany

    April 3, 2020

    Read time: 2 min

    Key takeaways
    Overview

    The article discusses the impact the Coronavirus (COVID-19) crisis is having on competition law and competition law regulators in Germany, and provides a number of useful links for further reading on these issues.

    Read the full article in German here.

    In depth
    Authors
    More insights

  • 401(k) and 403(b) Plans Under the CARES Act: Implementing Special Employee Relief

    401(k) and 403(b) Plans Under the CARES Act: Implementing Special Employee Relief

    ARTICLE / CLIENT ALERT

    401(k) and 403(b) Plans Under the CARES Act: Implementing Special Employee Relief

    April 3, 2020

    Read time: 3 min

    Key takeaways
    Overview

    Among the many aspects of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) passed by Congress and signed into law, are those that cover tax-qualified retirement plans, including 401(k) plans and 403(b) plans. As described in greater detail in our prior Alert, with respect to plan participants who are impacted by the pandemic, the CARES Act increases the amount available to be taken as a loan and permits special repayable in-service distributions (“coronavirus-related distributions”) of up to $100,000, without early-withdrawal penalty taxes.

    Should New Provisions Be Implemented?

    • Like all in-service distributions, coronavirus-related distributions and higher loan amounts generally are unfavorable for long-term retirement saving.
    • A coronavirus-related distribution is only available to a plan participant who has been affected by COVID-19 and might be eligible to take a “hardship withdrawal” if offered by the plan.
    • Unlike a coronavirus-related distribution, a participant’s hardship withdrawal may be subject to a 10% penalty tax and will not be repayable.

    Implementation of New Provisions

    • The new CARE Act provisions can be implemented by plans immediately.
    • For a plan to implement the new distribution and loan provisions, the plan sponsor will need to adopt appropriate plan amendments, however, the amendments to a plan can be adopted at a later time.
    • Certain plan administrators, such as TIAA and Fidelity, that offer “pre-approved plans” (i.e., a form of plan document that has been determined by the Internal Revenue Service to meet tax requirements) are taking unilateral action to implement the CARES Act provisions automatically for all clients who have adopted their pre-approved plans.
      • A plan sponsor that does not want its plan to adopt one or more of the provisions must affirmatively opt out of the automatic changes by taking action, in some cases, within a very short time period.

    We are available to assist you with analyzing the impact of the new changes for your plan.

    Authored by Mark E. Brossman, David M. Cohen, Ian. L. Levin, Ronald E. Richman and Susan E. Bernstein.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    David M. Cohen

    Partner

    New York – 919 Third Avenue

    Ian L. Levin

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    More insights

  • Lenders and Other Dealmakers: Update on US Patent and Trademark Office and Copyright Office —  CARES Act Provides Limited Relief

    Lenders and Other Dealmakers: Update on US Patent and Trademark Office and Copyright Office — CARES Act Provides Limited Relief

    ARTICLE / CLIENT ALERT

    Lenders and Other Dealmakers: Update on US Patent and Trademark Office and Copyright Office — CARES Act Provides Limited Relief

    April 3, 2020

    Read time: 3 min

    Key takeaways
    Overview

    On March 31, 2020, pursuant to authority granted under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), the U.S. Patent and Trademark Office (“USPTO”) and the U.S. Copyright Office (“USCO”) each announced that it will, in limited cases, extend statutory filing deadlines in response to the COVID-19 pandemic.

    • The USPTO will extend by 30 days the time to file certain documents and remit certain fees that would have been due between March 27, 2020 and April 30, 2020, if the delay in filing or payment was due to the COVID-19 pandemic.
    • The USCO will allow additional time to make certain filings related to applications to register copyrights and requests by authors to terminate rights previously granted to third parties. As with the USPTO, a filer must demonstrate that the delay was due to the COVID-19 pandemic.

    Our prior Alert advised that during their closures due to the COVID-19 pandemic, the USPTO and USCO would continue to maintain their electronic filing systems and adopt certain revised procedures which enable lenders and other dealmakers to file documents to timely record their intellectual property rights. The available extensions announced by the USPTO and the USCO on March 31, 2020 generally do not impact the kinds of filings typically made by lenders and deal makers, namely, security interest grants and releases and ownership transfer filings. The extensions could, nonetheless, benefit lenders and other deal makers less directly. For example, borrowers may be able to meet the extended statutory filing deadlines to establish their intellectual property rights — assets that they have pledged as collateral to their lenders — and portfolio companies may be able to do the same. In any case, the relief granted is limited and processing delays continue to be the primary impact we anticipate for lending and other deal-related filings.

    Authored by Edward H. Sadtler, Scott M. Kareff and Jaclyn N. Malmed.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Scott M. Kareff

    Special Counsel

    New York – 919 Third Avenue

    More insights

  • Uncleared Margin Rules: BCBS and IOSCO Grant One-Year Extension on Phase 5/6 Implementation

    Uncleared Margin Rules: BCBS and IOSCO Grant One-Year Extension on Phase 5/6 Implementation

    ARTICLE / CLIENT ALERT

    Uncleared Margin Rules: BCBS and IOSCO Grant One-Year Extension on Phase 5/6 Implementation

    April 3, 2020

    Read time: 3 min

    Key takeaways
    Overview

    On April 3, 2020, the Basel Committee on Banking Supervision (“BCBS”) and the International Organization of Securities Commissions (“IOSCO”) agreed to a one-year extension of the deadline for completion of the final two margin requirement implementation phases for non-centrally cleared derivatives. The BCBS and IOSCO noted that, in light of challenges posed by the COVID-19 pandemic, including displacement of staff and the need for firms to focus recourses on managing current market volatility risk, the extension will provide additional operational capacity to firms while also facilitating covered entities in acting diligently to comply with the revised deadline requirements.

    Under the revised deadlines, covered entities with an aggregate average notional amount (“AANA”) of non-centrally cleared derivatives over $50 billion will become subject to the requirements on Sept. 1, 2021, while covered entities with an AANA of non-centrally cleared derivatives at or below $50 billion (but over $8 billion, which is the minimum threshold) will become subject to the requirements on Sept. 1, 2022. These changes are reflected in a revised version of the margin requirements (available here). The BSBC and IOSCO have noted that no other substantive changes are featured therein.

    Parties should note that the BCBS-IOSCO framework is not binding law, but the assumption is that U.S. regulators that adopted margin requirements based on the framework will also follow this change.

    Authored by Craig Stein and Atul Joshi.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Craig Stein

    Partner

    New York – 919 Third Avenue

    More insights